{"title":"PPIs Have It: Does Tegoprazan Affect Gastric Emptying and Produce Dyspeptic Symptoms?","authors":"José María Remes-Troche","doi":"10.1007/s10620-025-08857-8","DOIUrl":null,"url":null,"abstract":"<p><p>The potassium-competitive acid blockers (P-CABs) are a novel class of potent antisecretory drugs that unlike the proton pump inhibitors (PPIs) are not dependent on activated proton pumps, acting near maximally from the first dose, a pharmacokinetic advantage over PPIs. Tegoprazan, a novel P-CAB, offers potent and rapid acid suppression without delaying gastric emptying, distinguishing it from PPIs. This commentary contextualizes these results within the broader landscape of functional dyspepsia management, highlighting the potential benefits of tegoprazan in patients requiring antisecretory therapy, emphasizing the need for further research into its long-term impacts on motility, gut microbiota composition, and symptomatology. This analysis underscores how P-CABs may redefine antisecretory therapies.</p>","PeriodicalId":11378,"journal":{"name":"Digestive Diseases and Sciences","volume":" ","pages":"1283-1285"},"PeriodicalIF":2.5000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Digestive Diseases and Sciences","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10620-025-08857-8","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/19 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
The potassium-competitive acid blockers (P-CABs) are a novel class of potent antisecretory drugs that unlike the proton pump inhibitors (PPIs) are not dependent on activated proton pumps, acting near maximally from the first dose, a pharmacokinetic advantage over PPIs. Tegoprazan, a novel P-CAB, offers potent and rapid acid suppression without delaying gastric emptying, distinguishing it from PPIs. This commentary contextualizes these results within the broader landscape of functional dyspepsia management, highlighting the potential benefits of tegoprazan in patients requiring antisecretory therapy, emphasizing the need for further research into its long-term impacts on motility, gut microbiota composition, and symptomatology. This analysis underscores how P-CABs may redefine antisecretory therapies.
期刊介绍：
Digestive Diseases and Sciences publishes high-quality, peer-reviewed, original papers addressing aspects of basic/translational and clinical research in gastroenterology, hepatology, and related fields. This well-illustrated journal features comprehensive coverage of basic pathophysiology, new technological advances, and clinical breakthroughs; insights from prominent academicians and practitioners concerning new scientific developments and practical medical issues; and discussions focusing on the latest changes in local and worldwide social, economic, and governmental policies that affect the delivery of care within the disciplines of gastroenterology and hepatology.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
